OR WAIT null SECS
The new progesterone active pharmaceutical ingredient, used captively by Pfizer for the past four years, reduces carbon footprint by more than 70%
Pfizer CentreOne, a contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs), has introduced Enviero progesterone to its contract customers. The API is made via a proprietary synthesis that significantly reduces waste, greenhouse gas emissions, and the use of hazardous solvents.
Overall, the process reduces overall carbon footprint by more than 70%, and eliminates the use of metal catalysts, according to the company. The process took more than 12 years to develop and uses a biocatalytic process based on plant sterols.
While Enviero is new to Pfizer CentreOne customers, Pfizer has used the compound as an intermediate for the past four years, and more than 500 metric tons have been manufactured to date for captive use. The compound, made exclusively at Pfizer’s Kalamazoo, MI, facility, is the first API to be launched from Pfizer CentreOne’s green-chemistry program.
Source: Pfizer CentreOne